Oxford Asset Management’s PTC Therapeutics PTCT Stock Holding History

Oxford Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,762	Closed	-$281K	–	671
2025 Q2	$281K	Buy	+5,762	New	+$274K	0.09%	340
2024 Q2	–	Sell	-9,313	Closed	-$271K	–	393
2024 Q1	$271K	Buy	+9,313	New	+$261K	0.28%	138
2018 Q4	–	Sell	-42,023	Closed	-$2.02M	–	2029
2018 Q3	$2.02M	Sell	42,023 -35,608	-46%	-$1.47M	0.04%	658
2018 Q2	$2.57M	Buy	77,631 +65,466	+538%	+$2.04M	0.05%	513
2018 Q1	$329K	Sell	12,165 -20	-0.2%	-$507	0.01%	1382
2017 Q4	$206K	Sell	12,185 -83,686	-87%	-$1.42M	﹤0.01%	1449
2017 Q3	$1.9M	Buy	+95,871	New	+$1.88M	0.04%	644
2017 Q1	–	Sell	-136,592	Closed	-$1.49M	–	1460
2016 Q4	$1.49M	Buy	+136,592	New	+$1.43M	0.05%	394

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oxford Asset Management's PTCT Position: Q3 2025 in Review

Oxford Asset Management sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 5,762 shares — an estimated $281K sold.

Oxford Asset Management first reported a position in PTCT in Q4 2016 and held it in 8 quarters. The position peaked at $2.57M in Q2 2018. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

Oxford Asset Management reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
Oxford Asset Management sold 5,762 PTC Therapeutics shares in Q3 2025, an estimated $281K.
Oxford Asset Management first reported a position in PTC Therapeutics in Q4 2016 and held it in 8 quarters.
Oxford Asset Management's PTC Therapeutics position peaked at $2.57M in Q2 2018.
293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Oxford Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.